← Back to Clinical Trials
Recruiting NCT06292897

NCT06292897 Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06292897
Status Recruiting
Phase
Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 25 participants
Start Date 2023-03-20
Primary Completion 2026-09-15

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 25 participants in total. It began in 2023-03-20 with a primary completion date of 2026-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI \> 27.5) and non-severely overweight/normoweight (BMI \< 27.5) patients affected by prostate carcinoma. ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients. iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.

Eligibility Criteria

Inclusion Criteria: * affected by prostate cancer Exclusion Criteria: \-

Contact & Investigator

Central Contact

Giancarlo Albo, MD,

✉ giancarlo.albo@policlinico.mi.it

📞 00390255034501

Frequently Asked Questions

Who can join the NCT06292897 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06292897 currently recruiting?

Yes, NCT06292897 is actively recruiting participants. Contact the research team at giancarlo.albo@policlinico.mi.it for enrollment information.

Where is the NCT06292897 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06292897 clinical trial?

NCT06292897 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 25 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology